Double your donation this Cancer Research Giving Day, 2 February 2023.

Postdoctoral Research Fellowships


Purpose of the Fellowship

Cancer Council Victoria offers Postdoctoral Fellowships to Victorian scientists who have recently completed a PhD and who would benefit from additional support to achieve a significant milestone in the research based on their thesis work. 

The application must establish that the research will be greatly enhanced by having the candidate spend additional time with the same research group (i.e., where the recipient was a PhD candidate).

2023 Available funding

To foster early-career researchers, we’re significantly increasing our investment in our Postdoctoral Research Fellowship program from $81,000 per annum to $450,000 per grant, across three years. 
Funds will be paid quarterly in advance to the administering institution, which will make payments to the recipient according to its internal arrangements.

Key dates 

Key dates for the 2023 round will be released shortly. 

Conditions of Postdoctoral Research Fellowships


At the conclusion of the fellowship, recipients must submit a report on their research to Cancer Council Victoria who may specify special reporting requirements or formats.

Recognition of Cancer Council Victoria

The fellowship holder must acknowledge the support of Cancer Council Victoria and (if applicable) any nominated fund, donation or bequest, in all publications, presentations and media announcements pertaining to the research for which the fellowship has been awarded. Cancer Council Victoria may specify from time to time a form of words to be used to acknowledge the support of Cancer Council Victoria and any nominated fund, donation or bequest.

Other funding sources

The fellowship holder may receive funding from other sources however the other funding must not be contingent on any naming rights pertaining to the candidate or the research.


If offered a fellowship, your Research Administrative Officer will need to certify that you have the relevant committee approvals e.g. Human Research Ethics Committee, Animal Experimentation Ethics Committee, Biosafety Committee. The fellowship funding will not commence until all approvals have been provided. 


Research Governance Unit
03 9514 6200

Current recipients

Dr Joanne Lundy  
Monash University 
The Endoscopic Ultrasound Molecular Evaluation of Pancreatic Cancer (EU-ME- PC) Study (Jul 2022 - Jun 2023) 
Validating endoscopic biopsies to guide better treatment selection in pancreatic cancer 

Dr Feng Yan
Monash University
Deciphering abnormal epigenetic characteristics in chemo-resistant stem cells using a transgenic mouse model of human T-cell acute lymphoblastic leukaemia (Jul 2022 - Jun 2023) 
Examine chemo-resistant T-cell acute lymphoblastic leukaemia cells and understand how they escaped from chemotherapy 

Dr Sibel Saya 
University of Melbourne 
Multi-cancer genomic risk assessment to target screening in general practice (Apr 2022 - Apr 2023)
DNA testing to predict risk of cancer in general practice 

Past recipients 

Dr. Marc Rigau Cortal  
University of Melbourne 
Optimisation of the phosphoantigen-reactive gamma-delta T-cell receptor for use in adoptive T-cell therapy against the most common blood and solid tumours in the Australian population  (Jan 2022 - Dec 2022)
Empowering human immune cells against blood and solid cancers

Dr. Stefan Bjelosevic 
University of Melbourne
Delineating mechanisms of metabolic regulation of epigenetic state in FMS-liketyrosine kinase 3 (FLT3)-driven acute myeloid leukaemia (AML) 
(Jul 2021 - Jun 2022)

Dr. Heidi Fettke
University of Melbourne 
Dissecting therapeutic vulnerabilities of advanced prostate cancer harbouringcompound androgen receptor alterations
(Jul 2021 - Jun 2022) 

Dr Edmond Kwan
Monash University 
Comprehensive circulating nucleic acid analysis to identify biomarkers for immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer
(mCRPC)  (Jan 2021 - Dec 2021)

Dr Peter Savas
Peter MacCallum Cancer Centre
Extending genomic profiling to understanding outcomes in clinical trials (Jan 2021 - Dec 2021)

Mr Charles Bell
The University of Melbourne
Identifying new drug targets to specifically reduce the activity of genes that are essential for cancer cells (Jul 2020-Jun 2021)

Dr Tanjina Kader
Peter MacCallum Cancer Centre
Development of a new test after a mammogram to help doctors and patients decide whether they should operate or save their breasts (Jul 2020-Jun 2021).

Dr Margs Brennan
The Walter and Eliza Hall Institute of Medical Research
Testing MCL - 1 inhibitor treatment in humanised MCL - 1pre-clinical mouse models of Philadelphia-like paediatric acute lymphoid leukaemia (Jul 2019-Dec 2020)

Dr Na Li
Peter MacCallum Cancer Centre
Discovering new genetic causes of familial breast cancer (Jan 2020-Dec 2020)

Dr Mohamed Saad
Hudson Institute of Medical Research
Identification of ADAM17-driven Molecular Events in Lung Cancer (Jan 2020-Dec 2020)

Dr James Whittle
The Walter and Eliza Hall Institute of Medical Research
Targeting cell survival pathways in breast cancer (Jan 2020-Dec 2020)

Dr Simon Preston
The Walter and Eliza Hall Institute of Medical Research
Targeting caspase-8 in T-regulatory cells as cancer immunotherapy in Hepatocellular carcinoma (Jan 2020-Jun 2020)

Dr Lara Edbrooke
The University of Melbourne
Rehabilitation in inoperable lung cancer - a cost-effectiveness evaluation (Jan 2020-Jun 2020)

Dr Pasquale Fedele
The Walter and Eliza Hall Institute of Medical Research
Targeting IRF4 in Multiple Myeloma (Jan 2019-Dec 2019)

Dr Rebecca Delconte
The Walter and Eliza Hall Institute of Medical Research
Increasing Natural Killer cell ability to detect and kill cancer cells (Jul 2018-Jun 2019)

Dr Shuai Li
The University of Melbourne
Understanding why and how environmental factors change breast cancer risk by studying genes (Jul 2018-Jun 2019)

Dr Hendrika Duivenvoorden
La Trobe Institute for Molecular Science
Validating markers that predict early breast cancer invasion (Jan 2018 - Dec 2018)

Dr Simon Hogg
Peter MacCallum Cancer Centre  
Developing drugs that promote the immune system to eliminate cancer  (Aug 2017-Jul 2018)  

Dr Tan Nguyen
The Walter and Eliza Hall Institute of Medical Research
Can we inhibit RNA degradation to help treat cancer?  (Jan 2018 - Dec 2018)

Dr Tuong Linh Nguyen
The University of Melbourne
Predicting a woman’s future risk of breast cancer from her mammograms (Jan 2018 - Dec 2018)

Dr Ashleigh Poh
The Olivia Newton-John Cancer Research Institute
Improving responsiveness to anti-cancer immunotherapy  (Jul 2017-Jun 2018) 

Dr Antonia Policheni
The Walter and Eliza Hall Institute of Medical Research
How does cell competition and cell death prevent childhood blood cancer? (Jan 2018 - Dec 2018)